Nasal challenge with allergen leads to maxillary sinus inflammation

Slides:

Advertisements

Similar presentations

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Advertisements

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion William T. Barchuk, MD, Anne Marie Salapatek,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Allergen immunotherapy: A practice parameter third update

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Fatty acids, inflammation, and asthma

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Chronic rhinosinusitis: Potential new use for topical sulfasalazine

Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Fatty acids, inflammation, and asthma

Fuad M. Baroody, MD, Se-Hoon Suh, MD, Robert M. Naclerio, MD

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Jerome A. Sigua, MD, Becky Buelow, MD, Dorothy S

Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity

Peter M. Wolfgram, MD, David B. Allen, MD

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Reply Journal of Allergy and Clinical Immunology

Ordinary vibratory angioedema is not generally associated with ADGRE2 mutation Zuotao Zhao, MD, PhD, Sascha Reimann, MD, Shan Wang, MD, Yuhan Wang, MD,

Jon Genuneit, MD, MSc Journal of Allergy and Clinical Immunology

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Ovalbumin content of influenza vaccines

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion William T. Barchuk, MD, Anne Marie Salapatek,

Basophils and eosinophils in allergic rhinitis

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

John A. Eckman, MD, Patricia M

What is an “eosinophilic phenotype” of asthma?

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis Sriram Vaidyanathan, MBBS, Peter Williamson,

John Leung, MD, Navneet Virk Hundal, MD, Aubrey J. Katz, MD, Wayne G

One step forward, 2 steps back: The enigma of preschool wheeze

Risk of oral food challenges

Biology of nasal polyposis

Martin Brasholt, MD, Florent Baty, PhD, Hans Bisgaard, MD, DMSci

Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis Carmen Rondón, MD, PhD, Javier.

Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis Iris M. Otani, MD, Arjun A. Anilkumar,

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Alvaro A. Cruz, MD, Robert M

Measles and immunomodulation

Nasal challenge with allergen leads to maxillary sinus inflammation

Päivi M. Salo, PhD, Samuel J. Arbes, DDS, MPH, PhD, Patrick W

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Charcot-Leyden crystal concentration in nasal secretions predicts clinical response to glucocorticoids in patients with chronic rhinosinusitis with nasal.

Environmental factors and eosinophilic esophagitis

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Nasal challenge with allergen leads to maxillary sinus inflammation Fuad M. Baroody, MD, Samantha M. Mucha, MD, Marcy deTineo, BSN, Robert M. Naclerio, MD Journal of Allergy and Clinical Immunology Volume 121, Issue 5, Pages 1126-1132.e7 (May 2008) DOI: 10.1016/j.jaci.2008.02.010 Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Challenge protocol for subjects, depicting time points of catheter insertion, sneezing and nasal symptom (Sxs) recording, and nasal and sinus lavage. Journal of Allergy and Clinical Immunology 2008 121, 1126-1132.e7DOI: (10.1016/j.jaci.2008.02.010) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Median sneezes and rhinorrhea and congestion scores for allergen (solid circles, n = 20) and control (open circles, n = 11) challenges: A, number of sneezes; B, rhinorrhea score; C, congestion score. The protocol is on the x-axis. Pre, Baseline prewash; Dil, diluent for the allergen extract, A, allergen challenge. ∗P ≤ .05 and †P < .01 versus respective diluent challenges. Journal of Allergy and Clinical Immunology 2008 121, 1126-1132.e7DOI: (10.1016/j.jaci.2008.02.010) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Median levels of mediators in the nasal cavity after allergen (solid circles, n = 20) and control (open circles, n = 11) challenges: A, albumin; B, histamine; C, ECP. The protocol is on the x-axis, and the labels are as in Fig 2. ∗P ≤ .05 and †P < .01 versus respective diluent challenges. Journal of Allergy and Clinical Immunology 2008 121, 1126-1132.e7DOI: (10.1016/j.jaci.2008.02.010) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Median number of eosinophils in the nasal cavity and maxillary sinus after allergen (solid circles, n = 20) and control (open circles, n = 11) challenges: A, nasal cavity; B, maxillary sinus. The protocol is on the x-axis, and the labels are as in Fig 2. ∗P ≤ .05 and †P < .01 versus respective diluent challenges. Journal of Allergy and Clinical Immunology 2008 121, 1126-1132.e7DOI: (10.1016/j.jaci.2008.02.010) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Median levels of mediators in the maxillary sinus after allergen (solid circles, n = 20) and control (open circles, n = 11) challenges: A, albumin; B, histamine; C, ECP. The protocol is on the x-axis, and the labels are as in Fig 2. ∗P ≤ .05 and †P ≤ .01 versus respective diluent challenges. Journal of Allergy and Clinical Immunology 2008 121, 1126-1132.e7DOI: (10.1016/j.jaci.2008.02.010) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 6 Percentage of eosinophils in blood, the maxillary sinus, and the nasal cavity after allergen challenge depicted as individual values with median bars. The maxillary sinus and nasal cavity data are presented as the median value for the peak LPR percentage of eosinophils for each subject. ∗P ≤ .01 versus blood value. Journal of Allergy and Clinical Immunology 2008 121, 1126-1132.e7DOI: (10.1016/j.jaci.2008.02.010) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions